Hub : Traits :

Headache pain in last month

485 significantly associated models · 67 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 149672809 151227371 6 1 1.4e-11 6.9e-11 5.1e-01 99 ECM1
2 1 155739430 157168420 1 1 2.7e-10 4.5e-16 3.9e-08 54 MEF2D
3 1 242590540 244359621 3 1 2.8e-09 1.8e-08 1.0e-01 92 CEP170
4 3 157594704 159140638 3 1 6.9e-08 6.9e-08 1.0e+00 100 RARRES1
5 4 87165758 88754060 1 1 1.7e-07 2.3e-08 1.9e-02 82 AFF1
6 6 12020241 13990267 2 1 2.4e-15 7.2e-16 7.8e-04 83 PHACTR1
7 6 25285943 26689223 1 1 8.6e-08 6.9e-10 4.8e-06 45 U91328.21
8 6 95831017 97756290 4 2 2.5e-26 1.8e-31 7.2e-04 92 FHL5 KIAA0776
9 8 8747245 9255927 1 1 6.7e-08 7.7e-08 2.7e-02 83 PPP1R3B
10 9 70961350 72562779 2 1 5.7e-08 2.5e-09 8.9e-03 81 TJP2
11 10 99973800 101244527 1 1 3.1e-08 9.0e-09 1.0e+00 100 HPSE2
12 11 56774260 58178587 1 1 6.5e-08 2.1e-06 9.6e-03 70 MED19
13 12 55677395 58303535 8 2 1.6e-40 1.6e-40 1.0e+00 100 LRP1 RAB5B
14 12 109739011 111873167 9 2 2.4e-10 2.5e-10 1.0e+00 100 ANKRD13A FAM216A
15 12 111910219 113517494 1 1 2.8e-07 5.0e-07 3.5e-01 97 HECTD4
16 16 74578110 76197034 2 1 4.5e-08 3.7e-08 1.4e-01 93 TMEM170A
17 17 42607368 45796313 21 8 2.4e-18 1.7e-16 1.0e+00 100 ACBD4 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 2.06 2 1 2.2 0.00 1.0e+00 CEP170 U91328.21
Depressed Affect (Nagel 2018) 9.90 7 7 15.6 1.00 2.8e-07 ARL17B CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Depression (Nagel 2018) 4.80 4 0 0.0 1.00 1.3e-04 ACBD4 ARL17B CRHR1-IT1 MED19
Intelligence (Savage-Jansen 2018) 2.57 4 1 2.2 -0.99 7.7e-04 CRHR1-IT1 MAPT RAB5B RP11-669E14.6
Neuroticism (Nagel 2018) 11.07 7 6 13.3 1.00 1.8e-07 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Schizophrenia (2018) 3.13 1 1 2.2 0.00 1.0e+00 U91328.21
Schizophrenia vs Biploar Disorder 3.02 1 0 0.0 0.00 1.0e+00 RP11-669E14.6
Worry (Nagel 2018) 5.55 6 5 11.1 1.00 2.1e-07 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Irritable Bowel Disease (IBD) 1.45 1 0 0.0 0.00 1.0e+00 ECM1
Reaction Time 1.75 2 1 2.2 0.00 1.0e+00 HECTD4 RAB5B
Verbal and Numeric Reasoning (VNR) 3.41 7 1 2.2 -0.97 4.9e-05 ARL17B CRHR1-IT1 FAM216A MAPT RAB5B RP11-669E14.6 U91328.21
Breast Cancer 4.16 5 3 6.7 1.00 5.1e-07 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Ovarian Cancer 8.67 5 5 11.1 -0.99 5.6e-05 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Coronary Artery Disease (CAD) 3.99 2 1 2.2 0.00 1.0e+00 HECTD4 PHACTR1
HDL Cholesterol 0.96 1 0 0.0 0.00 1.0e+00 AFF1
LDL Cholesterol 2.04 1 0 0.0 0.00 1.0e+00 HECTD4
Neuroticism (2016) 6.32 5 3 6.7 1.00 2.1e-07 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Primary Biliary Cirrhosis 4.44 6 0 0.0 -0.60 1.5e-01 CRHR1-IT1 HECTD4 LRP1 LRRC37A MAPT RP11-669E14.6
Schizophrenia (2014) 2.76 4 0 0.0 -0.98 1.9e-02 CEP170 CRHR1-IT1 LRRC37A MAPT
Triglycerides 1.80 1 1 2.2 0.00 1.0e+00 AFF1
Blood Eosinophil Count 7.75 12 10 22.2 -0.79 1.2e-03 ACBD4 ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 LRP1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Blood Platelet Count 1.60 8 5 11.1 0.71 3.3e-02 CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 MEF2D RP11-669E14.6 TMEM170A
Blood Red Count 11.38 11 8 17.8 0.81 1.3e-03 ACBD4 AFF1 ARL17B CRHR1-IT1 HECTD4 KANSL1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Blood White Count 2.62 7 2 4.4 0.36 3.8e-01 ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 MAPT RP11-669E14.6
Heel T-Score 3.80 11 9 20.0 -0.61 3.6e-02 ACBD4 AFF1 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 MEF2D RAB5B RP11-669E14.6
BMI 1.62 5 1 2.2 0.13 8.4e-01 CEP170 FHL5 LRP1 MEF2D RAB5B
Height 1.43 13 10 22.2 -0.54 4.5e-02 AFF1 ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 LRP1 LRRC37A MAPT MEF2D RARRES1 RP11-669E14.6 TMEM170A
Waist Hip Ratio (WHR) 5.06 7 6 13.3 0.99 3.1e-06 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MEF2D RP11-669E14.6
Systolic Blood Pressure 5.12 12 10 22.2 -0.32 2.8e-01 ANKRD13A CRHR1-IT1 FHL5 HECTD4 KANSL1 KIAA0776 MAPT MED19 MEF2D PHACTR1 RP11-669E14.6 TMEM170A
Smoking Status 2.05 3 1 2.2 0.00 1.0e+00 CRHR1-IT1 LRRC37A RAB5B
Allergy or Eczema 2.36 3 1 2.2 0.00 1.0e+00 LRP1 RAB5B TMEM170A
Cardiovascular Disease 1.57 4 1 2.2 0.54 4.6e-01 ANKRD13A FHL5 HECTD4 RAB5B
Hypothyroidism (self reported) 4.06 3 2 4.4 0.00 1.0e+00 FAM216A HECTD4 RAB5B
Respiratory disease 2.91 2 2 4.4 0.00 1.0e+00 LRP1 RAB5B
Lung FEV1/FVC ratio 5.60 8 4 8.9 -0.40 2.8e-01 CRHR1-IT1 LRP1 MAPT MEF2D PPP1R3B RAB5B RP11-669E14.6 TMEM170A
Lung FVC 10.75 11 8 17.8 -0.73 6.9e-03 AFF1 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT MEF2D RAB5B RARRES1 RP11-669E14.6
Neuroticism 11.10 8 6 13.3 0.99 1.2e-06 ARL17B CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Chronotype (morning person) 2.21 2 2 4.4 0.00 1.0e+00 ECM1 HECTD4
Hair Pigment 0.30 7 0 0.0 -0.62 9.9e-02 CRHR1-IT1 HECTD4 KANSL1 LRP1 MAPT PPP1R3B RP11-669E14.6
Tanning 0.49 1 0 0.0 0.00 1.0e+00 ECM1
Hand grip strength (left) 4.40 7 5 11.1 -0.81 1.5e-02 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6
Number of treatments/medications taken 3.25 2 0 0.0 0.00 1.0e+00 LRP1 MEF2D
Sensitivity / hurt feelings 11.98 7 6 13.3 1.00 9.9e-08 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Frequency of depressed mood in last 2 weeks 4.67 4 0 0.0 0.98 3.2e-03 ARL17B CRHR1-IT1 MED19 PPP1R3B
Relative age of first facial hair 11.79 6 6 13.3 0.99 9.2e-06 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Systolic blood pressure, automated reading 5.40 12 6 13.3 -0.39 1.9e-01 ANKRD13A CRHR1-IT1 FHL5 HECTD4 KANSL1 KIAA0776 MAPT MED19 PHACTR1 PPP1R3B RP11-669E14.6 TMEM170A
Angina 2.17 1 0 0.0 0.00 1.0e+00 PHACTR1
Vitamin and mineral supplements 3.81 2 1 2.2 0.00 1.0e+00 LRP1 RP11-669E14.6
Impedance of leg (right) 1.62 5 1 2.2 -0.96 3.0e-03 CRHR1-IT1 KANSL1 MAPT RAB5B RP11-669E14.6
Leg fat-free mass (left) 0.81 2 1 2.2 0.00 1.0e+00 HECTD4 RAB5B
Trunk fat percentage 2.06 7 0 0.0 -0.63 9.2e-02 CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Hand grip strength (right) 3.88 7 6 13.3 -0.77 2.6e-02 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6
Fed-up feelings 7.14 7 5 11.1 0.99 4.5e-07 CRHR1-IT1 HECTD4 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Frequency of unenthusiasm / disinterest in last 2 weeks 3.61 2 0 0.0 0.00 1.0e+00 ACBD4 PPP1R3B
Relative age voice broke 7.78 5 5 11.1 0.99 1.3e-04 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Age when periods started (menarche) 2.18 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 RP11-669E14.6
Heel bone mineral density (BMD) T-score, automated (left) 2.92 2 1 2.2 0.00 1.0e+00 MAPT PPP1R3B
High blood pressure 3.11 4 1 2.2 0.53 4.7e-01 ANKRD13A FHL5 HECTD4 RAB5B
Hayfever, allergic rhinitis or eczema 1.98 2 1 2.2 0.00 1.0e+00 LRP1 RAB5B
Multivitamins +/- minerals 2.13 1 0 0.0 0.00 1.0e+00 LRP1
Medication: Atenolol 1.62 1 0 0.0 0.00 1.0e+00 HECTD4
Medication: Levothyroxine sodium 4.17 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Sitting height 3.97 10 8 17.8 -0.60 4.9e-02 ACBD4 ARL17B CRHR1-IT1 ECM1 KANSL1 LRP1 LRRC37A MAPT PPP1R3B RP11-669E14.6
High blood pressure (mother) 2.53 2 0 0.0 0.00 1.0e+00 PHACTR1 TMEM170A
Body mass index (BMI) 1.49 4 1 2.2 0.54 4.6e-01 CEP170 HECTD4 PPP1R3B RAB5B
Impedance of leg (left) 1.82 6 3 6.7 -0.97 2.9e-04 CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6
Leg predicted mass (left) 0.81 2 1 2.2 0.00 1.0e+00 HECTD4 RAB5B
Trunk fat mass 1.56 3 0 0.0 0.00 1.0e+00 CEP170 HECTD4 MED19
Waist circumference 1.41 2 0 0.0 0.00 1.0e+00 HECTD4 RAB5B
Nervous feelings 5.59 7 2 4.4 1.00 1.7e-07 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Frequency of tenseness / restlessness in last 2 weeks 8.08 7 6 13.3 0.99 1.3e-06 ACBD4 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Hearing difficulty/problems with background noise 3.42 3 0 0.0 1.00 2.4e-03 CRHR1-IT1 KANSL1 RP11-669E14.6
Hair/balding pattern: Pattern 2 4.86 5 0 0.0 0.99 7.7e-05 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Forced vital capacity (FVC) 8.10 7 7 15.6 -0.89 3.3e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6 U91328.21
Heel bone mineral density (BMD) T-score, automated (right) 2.64 4 1 2.2 -0.83 1.7e-01 AFF1 MAPT PPP1R3B RP11-669E14.6
Ever unenthusiastic/disinterested for a whole week 3.67 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 LRRC37A
Qualifications: None of the above 2.31 1 1 2.2 0.00 1.0e+00 RAB5B
Mouth/teeth dental problems 3.47 4 0 0.0 -0.99 1.0e-03 CEP170 CRHR1-IT1 MAPT RP11-669E14.6
Heart attack 2.70 1 1 2.2 0.00 1.0e+00 PHACTR1
Allergy 2.31 2 1 2.2 0.00 1.0e+00 LRP1 RAB5B
Hayfever/allergic rhinitis (self-reported) 1.74 2 0 0.0 0.00 1.0e+00 LRP1 RAB5B
Fluid intelligence score 3.46 3 0 0.0 -0.15 8.5e-01 CRHR1-IT1 RAB5B U91328.21
Neuroticism score 10.26 8 7 15.6 0.99 7.2e-08 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 PPP1R3B RP11-669E14.6
Weight 1.06 3 2 4.4 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Impedance of arm (right) 3.29 9 6 13.3 -0.87 1.1e-03 AFF1 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Arm fat percentage (right) 1.21 1 0 0.0 0.00 1.0e+00 MED19
Trunk fat-free mass 0.96 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Hip circumference 1.26 3 1 2.2 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Time employed in main current job 4.01 3 0 0.0 0.00 1.0e+00 KANSL1 LRRC37A RP11-669E14.6
Worrier / anxious feelings 4.50 7 3 6.7 0.99 3.4e-06 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Frequency of tiredness / lethargy in last 2 weeks 3.43 2 1 2.2 0.00 1.0e+00 HECTD4 MED19
Hair/balding pattern: Pattern 3 11.57 6 6 13.3 -0.99 1.0e-05 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Number of live births 3.42 1 0 0.0 0.00 1.0e+00 CRHR1-IT1
Forced expiratory volume in 1-second (FEV1) 9.41 9 8 17.8 -0.78 7.3e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Qualifications: A levels/AS levels or equivalent 3.22 4 0 0.0 -0.99 7.2e-04 CEP170 CRHR1-IT1 RAB5B RP11-669E14.6
Asthma 3.07 3 1 2.2 0.00 1.0e+00 LRP1 RAB5B U91328.21
Medication: Ibuprofen (e.g. Nurofen) 9.90 10 1 2.2 0.98 2.0e-07 CRHR1-IT1 HECTD4 KIAA0776 LRP1 MAPT MEF2D PHACTR1 RP11-669E14.6 TJP2 U91328.21
Forced expiratory volume in 1-second (FEV1), Best measure 8.74 9 8 17.8 -0.79 7.1e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Impedance of arm (left) 3.81 8 5 11.1 -0.88 1.5e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Arm fat mass (right) 1.28 4 1 2.2 0.98 1.7e-02 CEP170 HECTD4 MED19 RAB5B
Trunk predicted mass 0.97 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Standing height 1.17 10 3 6.7 -0.34 3.1e-01 ARL17B CRHR1-IT1 HECTD4 KANSL1 LRP1 LRRC37A MAPT PPP1R3B RP11-669E14.6 U91328.21
Tense / 'highly strung' 2.88 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 PPP1R3B
Seen doctor (GP) for nerves, anxiety, tension or depression 1.64 1 0 0.0 0.00 1.0e+00 U91328.21
Hair/balding pattern: Pattern 4 22.01 6 6 13.3 -0.99 2.5e-05 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Birth weight of first child 2.34 3 1 2.2 0.00 1.0e+00 HECTD4 RAB5B TMEM170A
Peak expiratory flow (PEF) 5.96 9 7 15.6 -0.62 5.7e-02 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6 TMEM170A U91328.21
Medication: Paracetamol 14.93 12 11 24.4 0.97 3.2e-08 CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT MEF2D PHACTR1 RP11-669E14.6 U91328.21
Hypothyroidism/myxoedema (self-reported) 4.15 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Medication: Ventolin 100micrograms inhaler 2.05 1 0 0.0 0.00 1.0e+00 RAB5B
Forced vital capacity (FVC), Best measure 7.81 8 7 15.6 -0.86 3.1e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 U91328.21
Body fat percentage 1.56 3 0 0.0 0.00 1.0e+00 CEP170 LRP1 MED19
Leg fat percentage (right) 1.43 3 0 0.0 0.00 1.0e+00 FHL5 HECTD4 LRP1
Arm fat-free mass (right) 0.86 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Comparative body size at age 10 1.51 1 0 0.0 0.00 1.0e+00 U91328.21
Worry too long after embarrassment 4.19 5 1 2.2 0.98 8.4e-04 ARL17B CRHR1-IT1 MAPT MED19 RP11-669E14.6
Age at first live birth 2.97 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 RAB5B
Qualifications: College or University degree 4.55 7 7 15.6 -0.99 1.6e-06 CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6
Medication for pain relief, constipation, heartburn 11.98 12 8 17.8 -0.97 5.2e-08 CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT MEF2D PHACTR1 RP11-669E14.6 U91328.21
Angina (self-reported) 2.11 1 0 0.0 0.00 1.0e+00 PHACTR1
Migraine (self-reported) 10.60 7 4 8.9 1.00 5.2e-07 AFF1 ECM1 FHL5 KIAA0776 LRP1 MEF2D PHACTR1
Medication: Ibuprofen 7.81 4 1 2.2 0.93 2.2e-02 CRHR1-IT1 LRP1 MEF2D PHACTR1
Mean time to correctly identify matches 1.51 1 1 2.2 0.00 1.0e+00 HECTD4
Heart disease (mother) 2.82 1 0 0.0 0.00 1.0e+00 HECTD4
Whole body fat mass 1.34 3 0 0.0 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Leg fat mass (right) 1.40 3 0 0.0 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Arm predicted mass (right) 0.92 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Pulse rate, automated reading 1.73 2 1 2.2 0.00 1.0e+00 MEF2D RAB5B
Alcohol intake frequency. 5.42 8 4 8.9 0.95 8.0e-05 CRHR1-IT1 KANSL1 LRP1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Comparative height size at age 10 1.84 7 4 8.9 -0.54 1.7e-01 ARL17B CRHR1-IT1 HECTD4 LRRC37A MAPT RP11-669E14.6 U91328.21
Suffer from 'nerves' 2.71 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 RP11-669E14.6
Overall health rating 1.63 1 1 2.2 0.00 1.0e+00 CEP170
Leg pain on walking 3.17 1 0 0.0 0.00 1.0e+00 MAPT
Medication: Aspirin 1.40 1 0 0.0 0.00 1.0e+00 MEF2D
Supplements: Vitamin C 3.24 1 0 0.0 0.00 1.0e+00 RP11-669E14.6
Hypertension (Self-reported) 2.84 4 1 2.2 0.58 4.2e-01 ANKRD13A FHL5 HECTD4 RAB5B
Illnesses of father: Heart disease 3.10 1 0 0.0 0.00 1.0e+00 PHACTR1
Smoking status: Previous 2.45 2 0 0.0 0.00 1.0e+00 HECTD4 RAB5B
Whole body fat-free mass 0.88 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Leg fat-free mass (right) 0.76 2 1 2.2 0.00 1.0e+00 HECTD4 RAB5B
Arm fat percentage (left) 1.20 1 0 0.0 0.00 1.0e+00 MED19
Average weekly red wine intake 2.81 1 0 0.0 0.00 1.0e+00 MED19
Handedness (chirality/laterality): Left-handed 5.03 4 1 2.2 -0.99 1.9e-03 ARL17B CRHR1-IT1 LRRC37A RP11-669E14.6
Mood swings 8.52 6 6 13.3 0.99 3.7e-06 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Loneliness, isolation 4.58 2 0 0.0 0.00 1.0e+00 CRHR1-IT1 LRRC37A
Mouth/teeth dental problems: Mouth ulcers 6.78 6 5 11.1 1.00 6.5e-08 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Medication: Laxatives (e.g. Dulcolax, Senokot) 1.06 1 0 0.0 0.00 1.0e+00 ECM1
Back pain experienced in last month 1.70 1 0 0.0 0.00 1.0e+00 HECTD4
Mineral and other dietary supplements 1.64 1 0 0.0 0.00 1.0e+00 LRP1
Asthma (self-reported) 3.15 3 1 2.2 0.00 1.0e+00 LRP1 RAB5B U91328.21
Medication: Aspirin 1.22 1 0 0.0 0.00 1.0e+00 MEF2D
Forced expiratory volume in 1-second (FEV1), predicted percentage 8.95 10 8 17.8 -0.58 6.3e-02 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Whole body water mass 0.91 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Leg predicted mass (right) 0.76 2 1 2.2 0.00 1.0e+00 HECTD4 RAB5B
Arm fat mass (left) 1.21 3 1 2.2 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Average weekly champagne plus white wine intake 4.64 5 1 2.2 -0.99 3.0e-04 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Miserableness 5.63 5 3 6.7 0.99 8.5e-05 CRHR1-IT1 KANSL1 LRRC37A PPP1R3B RP11-669E14.6
Guilty feelings 5.20 6 0 0.0 1.00 2.8e-06 ARL17B CRHR1-IT1 KANSL1 LRRC37A MED19 RP11-669E14.6
Medication: Blood pressure 3.71 5 0 0.0 -0.99 1.2e-04 CRHR1-IT1 HECTD4 KANSL1 MAPT RP11-669E14.6
Supplements: Fish oil (including cod liver oil) 1.66 1 0 0.0 0.00 1.0e+00 LRP1
Medication: Paracetamol 12.69 11 7 15.6 0.97 1.8e-07 CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT PHACTR1 RP11-669E14.6 U91328.21
Basal metabolic rate 0.93 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Leg fat percentage (left) 1.42 2 0 0.0 0.00 1.0e+00 CEP170 LRP1
Arm fat-free mass (left) 1.07 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B
Irritability 5.35 7 3 6.7 0.99 8.3e-07 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Ever had prostate specific antigen (PSA) test 1.61 1 0 0.0 0.00 1.0e+00 U91328.21
Age started oral contraceptive pill 1.73 1 0 0.0 0.00 1.0e+00 RAB5B
Diastolic blood pressure, automated reading 3.86 4 4 8.9 -0.21 7.9e-01 CEP170 HECTD4 PPP1R3B U91328.21
Myopia 3.14 2 0 0.0 0.00 1.0e+00 LRP1 LRRC37A
Vascular/heart problems diagnosed by doctor 2.56 4 0 0.0 -0.55 4.5e-01 ANKRD13A FHL5 HECTD4 MEF2D
Pain experienced in last month 7.30 9 1 2.2 -0.98 7.4e-07 CEP170 CRHR1-IT1 FHL5 HECTD4 LRP1 MAPT PHACTR1 RAB5B RP11-669E14.6
Heart attack/myocardial infarction (self-reported) 2.67 1 1 2.2 0.00 1.0e+00 PHACTR1
Impedance of whole body 3.25 8 5 11.1 -0.89 1.3e-03 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Leg fat mass (left) 1.38 3 0 0.0 0.00 1.0e+00 CEP170 HECTD4 RAB5B
Arm predicted mass (left) 1.09 2 2 4.4 0.00 1.0e+00 HECTD4 RAB5B

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 11 0.315 1.8
GTEx Adipose Visceral Omentum 9 0.442 1.8
GTEx Adrenal Gland 7 0.480 1.9
GTEx Artery Aorta 13 0.437 1.9
GTEx Artery Coronary 10 0.845 2.2
GTEx Artery Tibial 19 0.505 2.0
GTEx Brain Caudate basal ganglia 5 0.543 1.8
GTEx Brain Cerebellar Hemisphere 8 0.537 1.9
GTEx Brain Cerebellum 6 0.303 1.8
GTEx Brain Cortex 6 0.580 1.9
GTEx Brain Frontal Cortex BA9 5 0.541 2.0
GTEx Brain Hippocampus 6 1.145 2.3
GTEx Brain Hypothalamus 4 0.678 1.9
GTEx Brain Nucleus accumbens basal ganglia 6 0.694 1.9
GTEx Brain Putamen basal ganglia 5 0.801 1.9
GTEx Breast Mammary Tissue 8 0.405 1.8
GTEx Breast Mammary Tissue (Male) 7 0.587 2.0
GTEx Breast Mammary Tissue (Female) 9 0.547 1.8
GTEx Cells EBV-transformed lymphocytes 9 0.632 2.1
GTEx Cells Transformed fibroblasts 14 0.333 1.8
GTEx Colon Sigmoid 7 0.479 1.9
GTEx Colon Transverse 9 0.436 1.9
GTEx Esophagus Gastroesophageal Junction 8 0.554 1.9
GTEx Esophagus Mucosa 14 0.422 1.8
GTEx Esophagus Muscularis 13 0.402 1.8
GTEx Heart Atrial Appendage 7 0.443 1.8
GTEx Heart Left Ventricle 8 0.523 1.7
GTEx Liver 4 0.558 1.8
GTEx Lung 9 0.313 1.8
GTEx Muscle Skeletal 10 0.346 1.8
GTEx Nerve Tibial 12 0.278 1.8
GTEx Ovary 6 0.661 2.0
GTEx Pancreas 9 0.551 1.9
GTEx Pituitary 5 0.448 1.8
GTEx Prostate 6 0.719 1.9
GTEx Skin Not Sun Exposed Suprapubic 11 0.447 1.9
GTEx Skin Sun Exposed Lower leg 10 0.275 1.8
GTEx Small Intestine Terminal Ileum 4 0.868 2.1
GTEx Spleen 5 0.354 1.9
GTEx Stomach 7 0.481 1.9
GTEx Testis 11 0.349 1.8
GTEx Thyroid 12 0.300 1.8
GTEx Uterus 6 1.058 2.3
GTEx Vagina 5 0.787 2.0
GTEx Whole Blood 7 0.351 1.7
METSIM Adipose 5 0.108 1.6
NTR Blood 7 0.291 1.7
ROSMAP Brain Pre-frontal Cortex 2 0.046 1.5
YFS Blood 4 0.087 1.5
CommonMind Brain Pre-frontal Cortex 8 0.149 1.6
The Cancer Genome Atlas Bladder Urothelial Carcinoma 3 0.181 1.6
The Cancer Genome Atlas Breast Invasive Carcinoma 4 0.091 1.6
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.273 1.7
The Cancer Genome Atlas Colon Adenocarcinoma 1 0.048 1.5
The Cancer Genome Atlas Esophageal Carcinoma 3 0.438 1.8
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.391 1.6
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 4 0.147 1.6
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 5 0.122 1.6
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 3 0.146 1.6
The Cancer Genome Atlas Brain Lower Grade Glioma 6 0.139 1.5
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.5
The Cancer Genome Atlas Lung Adenocarcinoma 5 0.170 1.7
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 5 0.200 1.6
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 4 0.251 1.6
The Cancer Genome Atlas Pancreatic Adenocarcinoma 3 0.181 1.6
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 4 0.301 1.7
The Cancer Genome Atlas Prostate Adenocarcinoma 8 0.173 1.6
The Cancer Genome Atlas Rectum Adenocarcinoma 3 0.434 1.6
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.281 1.8
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.6
The Cancer Genome Atlas Stomach Adenocarcinoma 3 0.178 1.6
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.5
The Cancer Genome Atlas Thyroid Carcinoma 7 0.136 1.6
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 2 0.394 1.8